Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201,903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unraveling TIMP1: a multifaceted biomarker in colorectal cancer.
Qiu X, Quan G, Ou W, Wang P, Huang X, Li X, Shen Y, Yang W, Wang J, Wu X. Qiu X, et al. Among authors: wang j, wang p. Front Genet. 2023 Sep 29;14:1265137. doi: 10.3389/fgene.2023.1265137. eCollection 2023. Front Genet. 2023. PMID: 37842645 Free PMC article.
Identification and validation of a novel signature based on cell-cell communication in head and neck squamous cell carcinoma by integrated analysis of single-cell transcriptome and bulk RNA-sequencing.
Wang J, Sun HC, Cao C, Hu JD, Qian J, Jiang T, Jiang WB, Zhou S, Qiu XW, Wang HL. Wang J, et al. Among authors: wang hl. Front Oncol. 2023 May 5;13:1136729. doi: 10.3389/fonc.2023.1136729. eCollection 2023. Front Oncol. 2023. PMID: 37213285 Free PMC article.
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
Fu Y, Wang A, Zhou J, Feng W, Shi M, Xu X, Zhao H, Cai L, Feng J, Lv X, Zhang X, Xu W, Zhang Z, Ma G, Wang J, Zhou T, Zhao D, Fang H, Liu Z, Huang JA. Fu Y, et al. Among authors: wang j, wang a. Front Oncol. 2023 Jun 27;13:1236311. doi: 10.3389/fonc.2023.1236311. eCollection 2023. Front Oncol. 2023. PMID: 37441428 Free PMC article.
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial.
Fang X, Zhu N, Zhong C, Wang L, Li J, Weng S, Hu H, Dong C, Li D, Song Y, Xu D, Wang J, Sun L, Wang J, Wang Z, Cao H, Liao X, Yu N, Xiao Q, Mi M, Zhang S, Ding K, Yuan Y. Fang X, et al. Among authors: wang l, wang j, wang z. EClinicalMedicine. 2023 Jul 27;62:102123. doi: 10.1016/j.eclinm.2023.102123. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37554125 Free PMC article.
201,903 results
You have reached the last available page of results. Please see the User Guide for more information.